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Joshua S Manusow1, Leila Khoja2, Nataly Pesin1, Anthony M Joshua2 and Efrem D Mandelcorn1*Abstract
We report on a 36-year-old woman treated with the anti PD-1 antibody Pembrolizumab for metastatic cutaneous
melanoma in the first line setting. She achieved a complete response and then relapsed with metastases to the
vitreous cavity with an associated angiographically determined retinal vasculitis. Vitreous metastasis without
choroidal involvement is unusual and may be due to individual cell extravasation, vitreous hemorrhage containing
malignant cells, or direct spread through the optic nerve. This finding highlights the need for immune sanctuary
sites to be monitored in the presence of PD-1 inhibition and we hypothesize that the use of PD-1 inhibitor
potentiated the patient’s angiographically determined retinal vasculitis.
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Retinopathy (MAR)Background
Pembrolizumab is an anti-programmed cell death-1
antibody (PD-1) currently under clinical evaluation pri-
marily for metastatic cutaneous melanoma as well as
lung cancer. The activity and relapse characteristics of
melanoma and pembrolizumab in immune sanctuary
sites has been incompletely reported to date. In this case
report, we identify a 36 year old female who achieved a
complete response and then relapsed with angiographic-
ally determined retinal vasculitis and melanoma cells
within the vitreous cavity. Isolated vitreous metastasis is
rare with just 18 previously reported cases in the world
literature [1] and highlights the issue of melanoma
within immune sanctuary sites in the setting of PD1 in-
hibition. We discuss the possible mechanisms and diag-
nostic pitfalls associated with this condition.Case presentation
A 36-year-old female, previously well, presented with a
2.4 mm ulcerated melanoma, with 1 mitosis/10 high* Correspondence: efrem.mandelcorn@utoronto.ca
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unless otherwise stated.powered fields, over her left back. The remainder of her
medical, family, and social history was noncontributory.
Following initial wide local resection and negative senti-
nel lymph node biopsy, she remained well with normal
surveillance CT scans. Five years later, she developed
hematuria and was found to have melanoma bladder
metastases. Whole body staging investigations revealed a
normal MRI brain and widespread metastatic disease in
the perinephric soft tissue, left adnexa, lung and pleura.
BRAF mutation testing of her primary was negative and
she was enrolled into a phase I clinical trial of pembroli-
zumab (10 mg/kg q3 weekly) approximately 5 months
after the diagnosis of metastatic disease. After 3 doses,
she complained of left sided blurred vision and mild an-
terior uveitis was diagnosed which was treated with
prednisolone eye drops. She continued on pembrolizu-
mab and was documented to be in complete response
after 15 treatments (approximately 10 months of treat-
ment). Shortly thereafter, she was admitted with grade 3
pneumonitis secondary to pembrolizumab treatment, re-
quiring intravenous steroids. A full body CT scan con-
firmed ongoing complete response. At this time she also
complained of blurred vision.
On examination her visual acuity was 20/20 OD and
20/200 OS. Her intraocular pressures were normal. Slit-ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Manusow et al. Journal for ImmunoTherapy of Cancer 2014, 2:41 Page 2 of 4
http://www.immunotherapyofcancer.org/content/2/1/41lamp examination of both eyes was unremarkable. Her
left fundus examination demonstrated clumped cellular
material in the vitreous [Figure 1], more so in the anter-
ior than posterior vitreous. The vitreous cells did not
have the classical clinical appearance of inflammatory
cells, as they were adherent in small clusters with no
collateral destruction of the surrounding vitreous gel.
Fluorescein angiography (IVFA) [Figure 2a-b] demon-
strated significant angiographically determined retinal
vasculitis with leakage from retinal vessels. There was no
macular edema. Laboratory testing for syphilis and toxo-
plasmosis was negative. A MRI did not appear to show
brain metastasis.
With high suspicion for metastatic melanoma to the
vitreous, a diagnostic vitrectomy was performed.
The vitreous biopsy contained tightly cohesive groups
and isolated tumour cells with pleomorphic nuclei and
prominent nucleoli [Figure 3]. The cells stained posi-
tively for vimentin, S-100 protein, Melan A, HMB45,
and pancytokeratin (AE1/AE3) by immunohistochemis-
try. These findings confirmed the diagnosis of metastatic
malignant melanoma in the vitreous cavity.
The patient improved post-operatively with a visual
acuity of 20/20. A repeat IVFA demonstrated complete
resolution of retinal vascular leakage (Figure 2c) and a
24–2 humphrey visual field was entirely normal. A post-
operative electroretinogram (ERG) demonstrated normal
rod and cone function and no flat B-wave.
Two months later the patient presented with acute on-
set apraxia but no other neurological deficits. A 7 mm
post-gadolinium enhancing nodule associated with intra-
parenchymal hematoma suggestive of brain metastasis
was diagnosed by MRI. The previous MRI was reviewed
and it was determined that this nodule was present at a
size of 1 mm on the initial scan pre-vitrectomy. Shortly
thereafter, she had a recurrence of refractile retrolental
cells in the left eye and a few vitreous cells in the right
eye and was subsequently treated with external beamFigure 1 Retrolental cells. Slit lamp photograph of the left eye
disclosing cohesive, pigmented, retrolental cells.radiation (20 Gy). She is currently being actively followed
with surveillance imaging. The lesion in the brain subse-
quently resolved spontaneously on MRI and she remains
in radiological complete response.
Conclusions
Though cutaneous melanoma commonly metastasizes to
the lymphatic system, central nervous system, liver, sub-
cutaneous tissues, and lung, it accounts for only 2 % of
primary tumors metastasizing to the uvea. [2] Our case
highlights the unusual nature of metastases directly to
the vitreous humor with no evidence of uveal involve-
ment. The mechanism of metastases to the vitreous is
unclear but may include (i) migration/extravasation of
single malignant cells through the retinal vessels into the
retrohyaloidal space [1] (ii) migration with vitreous
hemorrhage, originating from retinal vessels containing
malignant cells [1] or (iii) seeding directly through the
optic nerve [2]. In our case, despite the initial report of a
negative MRI, a brain nodule did exist making the mech-
anism of optic nerve seeding possible. A single intraret-
inal hemorrhage noted intra-operatively may have also
been the point of access of the malignant cells [1].
The development of secondary disease within the eye
despite a radiological complete response highlights the
phenomenon of recurrence within immune privileged
sites. These are classically considered to be the eyes, pla-
centa or testes but not the brain or central nervous sys-
tem (CNS) per se [3]. Such sites lack or have minimal
lymphatic drainage and have an immunosuppressive en-
vironment thought to be protective under normal physio-
logical circumstances. The CNS is only partially protected
against the systemic immune response by the blood brain
barrier as it has resident macrophages. Dendritic cells ne-
cessary for antigen presentation and T-cell activation are
additionally able to circulate in the meninges and choroid
plexus but not in the normal parenchymal tissue or peri-
vascular spaces. Therefore even with highly active drugs
such as targeted therapy in the BRAF mutant population
or with the new checkpoint inhibitors (CTLA-4 and PD-
1/PDL-1 inhibitors) which potentiate the immune re-
sponse in tumor, relapse at immune privileged sites will
continue to be problematic. Ipilimumab, a CTLA-4
inhibitor, has shown efficacy in the treatment of brain
metastases in a small phase II study [4]. Trials to date on
Pembrolizumab have allowed recruitment of patients with
stable brain metastases (not requiring steroid treatment)
but specific activity in the CNS is yet to be reported [5].
To our knowledge, there are no reports of vitreous re-
lapse with ipilimumab.
Additionally, this patient presented with significant an-
giographically determined retinal vasculitis. This vasculitis
may be related directly to the ocular metastasis or a para-
neoplastic phenomenon. The fact that the angiographically
Figure 2 Retinal vasculitis. Fluorescein angiogram of the left eye discloses a) diffuse retinal vasculitis in the mid frame with b) leakage in the
late frame and c) resolution of vasculitis following vitrectomy.
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following vitrectomy (Figure 2c) in the absence of any
other treatment suggests that it is a local immune/para-
neoplastic effect. Paraneoplatic associated phenomena are
reported in the retina, including melanoma associated
retinopathy (MAR) and cancer associated retinatopathy
(CAR). These present with photopsia, loss of vision, nega-
tive electroretinographic waveforms, central scotoma, ret-
inal vessel attenuation, vasculitis, vitritis, macular edema
and eventually retinal atrophy [6,7]. The common mech-
anism is molecular mimicry; malignant cells that are
antigenically similar to retinal antigens stimulate the im-
mune system and lead to autoimmune injury of the ret-
ina. If our patient’s vasculitis is related to a paraneoplastic
phenomenon, the lack of electronegative ERG suggests
that a non-bipolar cell retinal antigen was targeted. The
physiological role of the PD-1/PDL1 axis is believed to
protect tissue from immune recognition. Importantly,
limited evidence suggests that it may also protect theFigure 3 Histopathology. Photomicrograph shows cohesive groups of m
nuclei with prominent nucleoli and abundant cytoplasm. a) Hematoxylin a
positive staining for c) S-100 stain, 40× and d) microphthalmia stain, 63×.retinal pigment epithelia (RPE) which may explain the ab-
sence of RPE and ERG changes in our patient [8].
One hypothesis is that the PD-1 inhibitor potentiated
an immune response against either similar retinal anti-
gens or melanoma cells within the retinal vessels leading
to inflammation of surrounding peripheral tissue and
secondary angiographically determined retinal vasculitis
in our patient. Indeed, reported toxicities from this class
of drugs include other autoimmune/inflammatory events
including nephritis, thyroiditis and endophthalmitis [9].
Thus, we suspect that the angiographically determined
retinal vasculitis in our case may have been a paraneo-
plastic phenomenon to non-bipolar cell retinal antigens
epitopically similar to those of melanoma. Alternatively,
the angiographically determined retinal vasculitis could
have been the result of an enhanced, local, inflammatory
response to melanoma cells in an anti-PD-1 molecular
environment which showed dramatic resolution once
the melanoma cell burden was removed by vitrectomy.alignant epithelioid cells displaying pleomorphic round eccentric
nd eosin, 63× b) Diff-Quik, 100× . Immunohistochemistry discloses
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http://www.immunotherapyofcancer.org/content/2/1/41In summary, we present the rare case of cutaneous
melanoma with metastasis to the vitreous cavity without
choroidal involvement but associated angiographically
determined retinal vasculitis in the presence of PD1
blockade with pembrolizumab. This case highlights the
need for vigilance in dealing with check-point blockade
antibodies and immune privileged sites, as well as the
need to be aware of a broad range of auto-immune phe-
nomena that can occur.
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